Adam Kosti Successfully Defends PhD Dissertation (Penalva Lab)

June 21, 2021

Join us in congratulating Adam Kosti of the Penalva Lab for successfully defending his dissertation, “microRNA-Transcription Factor Networks in Gliomagenesis” last week. Mentor: Dr. Luiz Penalva Program: PhD in Integrated Biomedical Sciences Discipline: Cancer Biology   Way to go Adam!       __________________________________________________________ Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey […]

Please welcome the Greehey CCRI summer 2021 interns

June 7, 2021

                    Greehey CCRI would like to welcome the 2021 Donald G McEwen, Memorial Summer Undergraduate Research Program students. Gaby Ruban – Dr. Chen Misa Ito – Dr. Ignatius Jingsi Zhou – Dr. Kitagawa Hoang Dinh  – Dr. Libich Gabriella Quintanilla – Dr. Penalva Shresth Arya – […]

Cancer Research: Deciphering the role of intestinal crypt cell populations in resistance to chemotherapy (Penalva Lab)

March 30, 2021

Carla Frau, Catherine Jamard, Gaspard Delpouve, Gabriela D. A. Guardia, Christelle Machon, Camilla Pilati, Clementine Le Neve, Pierre Laurent-Puig, Jérôme Guitton, Pedro A. F. Galante, Luiz O. Penalva, Jean-Noel Freund, Christelle de la Fouchardière and Michelina Plateroti Abstract Intestinal crypts are composed of heterogeneous and highly plastic cell populations. Lgr5high-stem cells (SC) are responsible for homeostatic renewal, but other cells can revert to an SC-like phenotype to maintain epithelial integrity. Despite their distinct roles in orchestrating homeostasis, both populations have been designated as […]

Development: The murine intestinal stem cells are highly sensitive to the modulation of the T3/TRα1-dependent pathway (Penalva Lab)

March 30, 2021

Matthias Godart, Carla Frau, Diana Farhat, Maria Virginia Giolito, Catherine Jamard, Clementine Le Nevé, Jean-Noel Freund, Luiz O. Penalva, Maria Sirakov, Michelina Plateroti Abstract The thyroid hormone T3 and its nuclear receptor TRα1 control gut development and homeostasis through the modulation of intestinal crypt cell proliferation. Despite increasing data, in-depth analysis on their specific action on intestinal stem cells is lacking. By using ex vivo 3D […]

MDPI: Musashi1 Contribution to Glioblastoma Development via Regulation of a Network of DNA Replication, Cell Cycle and Division Genes (Penalva Lab)

March 30, 2021

Mirella Baroni 1,†,  OrcID,Caihong Yi 1,2,†,  Saket Choudhary 3,†,  Xiufen Lei 1,  Adam Kosti 1,4,   Denise Grieshober 1,  Mitzli Velasco 1,  Mei Qiao 1,  Suzanne S. Burns 1,‡,  Patricia R. Araujo 1,  Talia DeLambre 1,  Mi Young Son 5,  Michelina Plateroti 6,  Marco A. R. Ferreira 7,  Paul Hasty 5,  and. Luiz O. F. Penalva […]

MDPI: Synergism of Proneurogenic miRNAs Provides a More Effective Strategy to Target Glioma Stem Cells (Penalva & Pertsemlidis Labs)

January 14, 2021

Adam Kosti, Rodrigo Barreiro, Gabriela D. A. Guardia, Shiva Ostadrahimi, Erzsebet Kokovay, Alexander Pertsemlidis, Pedro A. F. Galante, Luiz O. F. Penalva Simple Summary miRNAs function as critical regulators of gene expression and have been defined as contributors to cancer phenotypes by acting as oncogenes or tumor suppressors. Based on these findings, miRNA-based therapies have been explored in the treatment of many […]

MDPI: MSI1 Promotes the Expression of the GBM Stem Cell Marker CD44 by Impairing miRNA-Dependent Degradation

December 5, 2020

Rebecca Pötschke  1,2,† Jacob Haase 1,†,  Markus Glaß 1  Sebastian Simmermacher  3,Claudia Misiak 1,Luiz O. F. Penalva 4,5  Caspar D. Kühnöl, 2 and Stefan Hüttelmaier  1, Simple Summary Glioblastoma (GBM) is the most lethal brain tumor with a median survival rate of approximately 14 months. GBM patients commonly suffer from tumor recurrence, indicating that populations of chemo/radio-resistant stem cell-like tumor cells […]

Luiz O.F. Penalva PhD Awarded CPRIT Grant to Study New Glioblastoma (GBM) Regulator

August 20, 2020

PROJECT SUMMARY Glioblastoma (GBM) is the most common and most aggressive brain tumor type among adults with a 14 months average patient survival. Despite all genomic efforts in recent years, novel therapies based on GBM common mutations and alterations have been disappointing. To build an alternative route, we have been focusing on oncogenic RNA binding […]

Genome Biology: The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation.

August 20, 2020

Background RNA-binding proteins (RBPs) function as master regulators of gene expression. Alterations in RBP expression and function are often observed in cancer and influence critical pathways implicated in tumor initiation and growth. Identification and characterization of oncogenic RBPs and their regulatory networks provide new opportunities for targeted therapy. Results We identify the RNA-binding protein SERBP1 […]